AdaptHealth Q3 revenue up 6.3% to $804M; net loss $454M on $512M goodwill impairment; cuts FY EBITDA guidance

AdaptHealth Corp.

2023-Q3 EPS reported -$3.37 revenue$2,341,943,000

Net revenue $804.0M (+6.3% YoY); net loss $454.1M vs prior year income $16.1M due to $511.9M goodwill impairment.
Adjusted EBITDA $161.2M (+0.6% YoY); YTD cash from ops $325.4M, free cash flow $76.6M.
FY23 guidance: revenue narrowed to $3.160–3.185B; EBITDA lowered to $630–650M (from $650–680M). Capex 10–12%; FCF 3–4% unchanged.
Subsequent to quarter-end, repurchased $19.4M of common stock under share repurchase authorization.
Management cites sleep product growth for record revenue; Humana contract delays weighed on EBITDA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AdaptHealth Corp. reported third quarter ended September 30, 2023 results: revenue $804.0 million, net income Net loss attributable to AdaptHealth Corp. was $454.1 million. Guidance lowered.

Period: third quarter ended September 30, 2023
Revenue: $804.0 million
Net income: Net loss attributable to AdaptHealth Corp. was $454.1 million
Guidance: lowered
Result: reported results

Exact text from the filing

quarter ended September 30, 2023. Third Quarter Results and Highlights All comparisons are to the quarter ended September 30, 2022 unless otherwise stated. • Net revenue was $804.0 million compared to $756.5 million, an increase of 6.3%. • Net loss attributable to AdaptHealth Corp. was $454.1 million compared to net income of $16.1 million, largely resulting from a

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

AdaptHealth Corp. filing history →

Source: SEC EDGAR

accession 0001628280-23-037167

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.